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Abstract 
Myogenesis a complex process characterized by both biochemical nd morphological differentiation. Recent ransfection 
studies uggested a close relationship between the GLUT 3 transporter and the myogenic ability of rat skeletal L6 myoblast. 
In this study, the myogenic properties of GLUT 3- mutants were examined. Studies using three different GLUT 3- mutants 
(D2, D9 and D23) revealed that these mutants were defective not only in the GLUT 3 transporter, but also in the expression 
of myogenesis-associated g nes. The properties of mutant D23 were further characterized. Overexpression of an exogenous 
functional GLUT 3 transporter was unable to restore the myogenic defects of this mutant. This mutant was subsequently 
found to be altered in components acting on at least two different sites of the L6 myogenic pathway. Transfection studies 
revealed that mutant D23 was deficient in component(s) essential for the myogenin promoter activity. The second component 
was required for the transcription of muscle-specific protein genes, as overexpression f myogenin was unable to rescue the 
inability of this mutant o express muscle-specific genes and to form myotubes. Mutant D23 was therefore thought o be 
deficient in a regulatory component which controlled the expression of GLUT 3, myogenin and muscle-specific genes. 
© 1998 Elsevier Science B.V. All rights reserved. 
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1. Introduction 
Rat L6 myoblast is a permanent cell line originally 
isolated from embryonic skeletal muscles [1]. It is 
characterized by its ability to form multinucleated 
myotubes. Myogenesis is a complex process consist- 
ing of both biochemical and morphological differen- 
tiation [2]. A family of structurally related basic he- 
lix-loop-helix (bHLH) transcription factors, MyoD, 
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Myf-5, Myf-4/myogenin, and Myf-6/MRF-4/hercu- 
lin, is closely associated with myogenic regulation 
[3-5]. Inhibition of myf-5 translation blocks myoge- 
nin expression and myogenic differentiation [6,7]. 
Myogenin expression is normally repressed in prolif- 
erating myoblasts, and is up-regulated rapidly during 
myogenesis [8-10]. Transcription of myogenin and 
muscle-specific contractile protein genes (such as my- 
osin heavy chain (MHC), myosin light chain (MLC) 
and troponin T (TnT)) is dependent on the binding 
of the myogenin oligomeric complex to the E box 
(CANNTG) and the AT-rich sequence motifs present 
in these muscle-specific genes [3,4,11]. 
Eukaryotic glucose transport systems have been 
examined through a combination of biochemical, 
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molecular biological, and biophysical approaches 
[12-18]. All mammalian cells contain one or more 
members of the glucose transporter (GLUT) super- 
family. This GLUT family consists of six function- 
ally distinct proteins (GLUT 1, 2, 3, 4, 5 and 7) that 
share significant sequence similarity. The GLUT 1 
transporter is comprised of 12 transmembrane t~-hel- 
ical segments (TM) with the amino and carboxyl 
termini and a large connecting loop between TM6 
and TM7 oriented intracellularly [12-18]. While oth- 
er GLUT isoforms exhibit similar structural proper- 
ties as the GLUT 1 transporter, they also contain a 
considerable divergence in their amino acid sequen- 
ces. These isoform-specific amino acid sequences may 
play important roles in determining the intrinsic ac- 
tivities of specific glucose transporters [13]. 
The rat myoblast glucose transport processes have 
been examined through a variety of different ap- 
proaches [19-28]. Rat L6 myoblasts possess the 
GLUT 1, 3 and 4 transporters [27,28]. The GLUT 1 
transporter is mainly responsible for glucose trans- 
port activity in proliferating lucose-starved myo- 
blasts, the GLUT 3 transporter is the predominant 
transporter in proliferating lucose-grown myoblasts, 
and the insulin-responsive GLUT 4 transporter is
present in a very high level in myotubes. 
Studies on the physiological roles of the rat myo- 
blast GLUT 3 transporter revealed a close correla- 
tion between its expression and the cells' myogenic 
ability. First, all independently isolated GLUT 3- 
mutants of rat skeletal myoblast (i.e. those harboring 
less than 20% of the L6 GLUT 3 level) are impaired 
in myogenesis [19,27]. Second, GLUT 3- mutants of 
rat cardiac myoblast are also defective in myogenesis 
[29]. Third, myotube formation is always preceded by 
a dramatic decrease of the GLUT 3 transcript and 
transport activity [27,30]. Fourth, cells retaining rel- 
atively high levels of the GLUT 3 transcript and 
transport activity are unable to form myotubes 
[27,30]. The relationship between GLUT 3 and myo- 
genesis was also examined by transfecting L6 myo- 
blast with the GL UT 3 sense or antisense cDNA [31]. 
Overexpression f the GLUT 3 transporter (3-5-fold 
of the L6 level) suppressed expression of myogenin 
and muscle-specific genes, and myotube formation. 
On the other hand, diminished GLUT 3 expression 
(to around 39% of the L6 level) reduced only myo- 
genin expression, but not the rates of fusion and ex- 
pression of muscle-specific genes. These studies 
showed that a critical level of the GLUT 3 trans- 
porter was essential for myogenesis. GLUT 3 was 
thought o regulate myogenesis by modulating the 
levels of signal transducers involved in the myogenic 
pathway [31]. 
In this study, the properties of a rat myoblast 
GLUT 3- mutant, D23, were examined. This mutant 
was thought o be altered in regulatory component(s) 
which modulate not only GLUT 3 expression, but 
also the transcription of myogenin and muscle-specif- 
ic genes. More importantly, this study revealed that 
different components were involved in regulating the 
myogenin promoter activity and the expression of 
muscle-specific genes. 
2. Methods and materials 
2.1. Cell culture 
Rat L6 skeletal myoblast was originally isolated by 
Yaffe [1]; clones D2, D9 and D23 were independent 
GLUT 3- mutants isolated from L6 cells [19,25]. 
Myoblasts were grown in Alpha Minimal Essential 
Medium (Life Technologies), supplemented with 50 
p.g/ml of gentamicin sulfate (Life Technologies) and 
10% v/v horse serum (Hyclone) [32,33]. Cells were 
seeded at a density of 1 )<10 6 cells per 150 mm 
Nunc plate, and were subcultured every 3 days. 
2.2. Plasmids and culture media 
Human myf-4, my f-5 and GLUT 3 cDNAs were 
purchased from the Repository of Human and 
Mouse DNA Probes and Libraries, ATCC. The 
GLUT 3 cDNA contains the complete GLUT 3 cod- 
ing sequence and its 3'UTR (115-2742 bp). MLC, 
MHC and TnT cDNAs were gifts obtained originally 
from B. Nadal Ginard [34]. The ~2-microglobulin 
cDNA was a gift from F. Daniel [35]. The mouse 
myogenin promoter constructs, pGSC and pGXC, 
were generous gifts from S.P. Yee [36]. Both con- 
structs consist of a chloramphenicol acetyltransferase 
(CAT) gene (1.6 kb) and a SV40 t-antigen sequence 
with poly(A) ÷ signal. The pGSC construct contains 
the full-length (1092 bp) myogenin promoter, whereas 
the pGXC construct contains only the first 133 bp of 
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the myogenin promoter [36]. The PGK-myogenin con- 
struct and the PKJ1AR vector were gifts from I.S. 
Skerjanc [37,38]. PGK-myogenin contains the 1.5 kb 
myogenin coding sequence placed under the control 
of the phosphoglycerate kinase promoter (PGK) 
[37,38]. 
2.3. Southern blot analysis 
Genomic DNAs were isolated from L6 and D23 
transfectants u ing a previously described procedure 
[2,31]. Ten ~tg of genomic DNA were digested with 
appropriate restriction enzymes and analyzed on a 
0.8% agarose gel. The gel was then transferred to 
an ICN Biotrans positive nylon membrane, cross- 
linked, probed with an [a-32p]dCTP-labeled cDNA 
probe, and exposed to Kodak X-OMAT AR film. 
2.4. Northern blot analysis 
density of 1.5 x 105 cells/well. Medium was aspirated 
and each well was washed with 10 ml of PBS. Nine 
hundred ~tl of uptake buffer (PBS containing 1mg/ml 
bovine serum albumin) were added to each well. 
Transport studies were carried out at 23°C and 
were initiated by adding 100 ~tl of radioactive sub- 
strate. At appropriate times, uptake was terminated 
by rapidly washing the cells twice (less than 15 s) 
with 10 ml of ice-cold PBS. Samples were taken at 
15, 30, 45 and 60 s after addition of radioactive sub- 
strate. Cells were solubilized with 1 ml of 0.1% Tri- 
ton X-100, and 0.8 ml aliquots were counted in 10 ml 
of scintillation fluid. Under this condition, the up- 
take of 2-deoxy-D-glucose (dGlc) was linear with 
time and over 95% of the internalized Glc were 
phosphorylated [22]. Cells in two wells from each 
plate were detached with 0.1% trypsin and counted 
using a Coulter counter. Studies were carried out in 
quadruplicate. Results were consistent in all cases. 
Poly(A)+RNAs were extracted from myoblasts us- 
ing the Invitrogen FastTrack it. Northern blot anal- 
ysis was carried out as described previously, using 
1 txg mRNA per sample [2,27]. The blot was probed 
initially with labeled ~2-microglobulin cDNA to de- 
termine sample loading, and then with myf-4, MHC, 
MLC and TnT cDNAs. The blot was stripped with 
60% formamide at 65°C for 2 h before hybridizing 
with a new probe. This was then exposed to Kodak 
X-OMAT AR film; the autoradiogram was analyzed 
using the JAVA Video Analysis software (Jandel Sci- 
entific). Measurements were made in the linear range 
of optical density. In some studies, band intensity 
from the phosphorimage was measured using Image 
Quant Software (Molecular Dynamics, Sunnyvale, 
CA). Two different poly(A)÷RNA preparations 
were used in each study. Samples from each prepa- 
ration were probed at least twice. The amount of 
mRNA present in each lane was normalized accord- 
ing to the amount of ~2-microglobulin mRNA 
present in each sample. In calculating the relative 
transcript levels, the amount in day 2 L6 culture 
was used as 100%. 
2.6. Enzyme assays 
[3-Galactosidase activity was measured according 
to the standard procedure [39]. Optical density of 
the solution was determined at a wavelength of 420 
nm; readings were within the linear range (0.2~0.8) 
of the assay. 
Chloramphenicol acetyltransferase (CAT) assays 
were carried out by first heating the sample at 65°C 
for 10 min to inactivate deacetylases, after which 
samples were centrifuged at 12000×g at 4°C for 10 
min. The supernatant was then used in the CAT 
assay [39]. 87.5 ~tl of the cell extract were incubated 
with 27 ~tl of 1 M Tris-HCl (pH 7.8), 64 ~tl of 5 mM 
chloramphenicol in water, and 1.5 lal of [3H]acetyl 
coenzyme A (ICN) for 2 h at 37°C. The reaction 
was terminated by transferring the sample to ice. 
Each sample mixture was extracted twice with 200 
~tl ice-cold ethyl acetate, mixed thoroughly by vortex- 
ing for 1 min. Samples were centrifuged for 5 min at 
12 000 × g. The amount of radioactivity present in the 
upper (organic) phase was then determined using 
Non-Aqueous Scintanalyzed Scintilene (Fisher). 
2.5. Whole cell transport studies 2.7. Fusion index determination 
Transport studies were carried out using six-well 
Falcon plates [22,23]. Cells were routinely plated at a 
Fusion index was used to determine the extent of 
myotube formation [19]. Five fields (at least 100 nu- 
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Fig. 1. GLUT 3 transcript levels in GLUT 3 mutants. Poly- 
(A)+RNA was isolated from day 2 and day 6 cultures of 
GLUT 3 mutants (D23, D2 and D9), and their parental L6 
myoblast. Northern blot studies were carried out as described 
in the text. Band intensities from the phosphorimage were 
measured using Image Quant Software (Molecular Dynamics, 
Sunnyvale, CA). GLUT 3 transcript levels were normalized ac- 
cording to the [~2-microglobulin transcript level in each sample. 
The day 2 L6 GLUT 3 transcript level was taken as 100%. The 
dotted bar and slashed bar denote samples from day 2 and day 
6 cultures, respectively. Standard deviations were calculated for 
three different samples. 
clei per field) per well were chosen to determine the 
extent of fusion. A myotube was scored only if it 
contained at least three nuclei [19]. 
2.8. Immunofluorescence studies 
Immunofluorescence studies were conducted using 
mouse monoclonal anti-myogenin (F5D) and anti- 
MHC (MF-20) antibodies [40]. The former was a 
generous gift from W.E. Wright [37], whereas the 
latter was obtained originally from the Developmen- 
tal Studies Hybridoma Bank. The rabbit anti-mouse 
CY3 antibody was purchased from Jackson Labora- 
tories. Samples were examined using a Zeiss Axioplot 
Immunofluorescence microscope. Pictures were cap- 
tured using Northern Exposure Software, cropped 
and resized by Adobe Photoshop Software and im- 
ported into Corel Draw for final placement before 
printing. 
2.9. Materials 
[~-32p]dCTP and [3H]acetyl coenzyme A were pur- 
chased from ICN. Reagents used in bacterial cultures 
were obtained from Difco. Restriction and modifying 
enzymes were from Pharmacia, whereas ~DNA Hin- 
dIII digest and ~,DNA BstEII digest were from New 
England Labs. All other chemicals were from com- 
mercial sources and were of the highest available 
purity. 
3. Resu l ts  
3.1. Myogenic ability of GLUT 3- mutants 
The myogenic ability of three independent GLUT 
3- mutants of rat skeletal myoblast was examined in 
this study. Mutant D2 was isolated from ethyl meth- 
anesulfonate-mutagenized L6 myoblast by its ability 
to grow in the presence of 0.1 mM 2-deoxy-D-glucose 
(dGlc) [19]. D9 and D23 myoblasts were two sponta- 
neous mutants isolated independently from L6 myo- 
blasts by their ability to grow in the presence of 0.05 
mM dGlc [19]. GLUT 3 transcript levels in day 2 
cultures of D23, D2, and D9 myoblasts were found 
to be 15%, 14% and 25% of that in L6 myoblasts, 
respectively, whereas day 6 cultures of L6, D23, D2 
and D9 harbored 31%, 1%, 10% and 7% of the day 2 
L6 level, respectively (Fig. 1). This showed that D2, 
D9 and D23 myoblasts were defective in GLUT 3 
expression. Previous studies also showed that day 2 
D23 myoblast possessed around 17% of the L6 
GLUT 3 transporter level [27]. 
The rates of fusion of D2, D9 and D23 myoblasts 
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Fig. 2. Myogenic ability of GLUT 3 mutants. Fusion indices 
were determined for the GLUT 3 mutants and their parental 
L6 myoblast. ©, 0,  A, and • denote the rates of fusion by 
L6, D2, D9 and D23 myoblasts, respectively. The standard er- 
ror was calculated for each cell line for each day (n = 18). Since 
these values were less than 2%, they were not apparent on the 
graph. 
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Fig. 3. Expression of myogenesis-associated genes in GLUT 3- mutants. Poly(A)+RNAs were isolated from day 2 and day 6 cultures 
of GLUT 3 mutants (D23, D2 and D9) and their parental L6 myoblast. Northern blot analysis was performed as described in the 
text. The levels of myf-5, myogenin, MLC and TnT mRNAs were determined by probing with their respective cDNAs. The day 2 L6 
level was taken as 100% for each probe. A, B, C and D indicate the levels of m)f-5, myogenin, MLC and TnT transcripts, respec- 
tively. The dotted bar and the slashed bar denote samples from day 2 and day 6 cultures, respectively. Standard eviations were cal- 
culated for three different samples. 
were determined over a 10 day period (Fig. 2). The 
fusion indices of rat L6 cells were 81% and 100% in 
day 6 and day 10 cultures, respectively. D2 cultures 
had reduced rates of fusion; day 6 and day 10 cul- 
tures had fusion indices of around 44% and 79%, 
respectively, whereas the corresponding values for 
mutant D9 were 11% and 16%, respectively. More 
interestingly, mutant D23 was unable to form myo- 
tubes, even though it had similar GLUT 3 transcript 
level as mutant D2. While this study showed that all 
GLUT 3- mutants were impaired in myogenesis, it 
also suggested that these mutants were altered in 
different myogenic omponents. 
3.2. Expression of myogenesis-assoeiated g nes in 
GLUT 3- mutants 
To further explore the myogenic defects of GLUT 
3- mutants, the expression of myogenesis-associated 
genes was examined. Cells were grown under condi- 
tions that promoted myotube formation. Poly- 
(A)+RNAs from these cells were probed with 
myf-5, myogenin, MLC, and TnT cDNAs (Fig. 3). 
Myf-5 transcript levels in day 2 GLUT 3- mutants 
(D2 (96%), D9 (107%), and D23 (84%)) were similar 
to that of L6 culture. While the day 6 L6 myf-5 tran- 
script level was reduced to around 31% of day 2 L6 
level, the reduction of this transcript was consider- 
ably smaller in GLUT 3- mutants. Myogenin tran- 
script levels in GLUT 3- mutants were significantly 
lower than that of day 2 L6 culture; about 7%, 77%, 
and 12% of the day 2 L6 myogenin level were ob- 
served in D23, D2, and D9 mutants, respectively 
(Fig. 3). The day 6 myogenin transcript levels in 
L6, D2 and D9 myoblasts were 200%, 128% and 
161% of that in day 2 L6 myoblast, respectively. 
More importantly, this transcript remained at a 
very low level in day 6 D23 myoblast. These studies 
showed that myogenin expression was reduced to dif- 
ferent extent in these GLUT 3- mutants. 
While both MLC and TnT transcripts were present 
in fairly low levels in day 2 cultures of D2 and D9 
myoblasts, they were elevated in day 6 cultures of 
both mutants (Fig. 3). On the other hand, only re- 
sidual levels of these two transcripts were present in 
day 2 and day 6 D23 cultures. The fact that mutant 
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D23 was essentially devoid of transcripts for myoge- 
nin and muscle-specific genes made this mutant an 
ideal cell line for studying the GLUT 3-associated 
myogenic events. 
3.3. Transfection of D23 myoblast with a GLUT 3 
cDNA 
If the GLUT 3 transporter is solely responsible for 
the myogenic defect in mutant D23, then expression 
of an exogenous GLUT 3 transporter may restore 
the myogenic ability of this mutant. In this study, 
the GLUT 3 cDNA was placed under the control 
of a dexamethasone-inducible MMTV promoter 
[41]. The concentration of dexamethasone (dex) 
used for induction was 0.1 ~tM; this concentration 
should not affect endogenous metabolic processes, as 
it altered myoblast metabolism only when used at 
concentrations above 12 ktM [42]. 
Stable D23 transfectants harboring the MMTV- 
GLUT 3 construct (D23/GLUT 3 myoblast) or the 
pMAMneo expression vector (D23/MMTV myo- 
blast) were selected using G418. Genomic DNAs 
from these transfectants were digested with HindIII 
and EcoRV, and then probed with 32p-labeled GLUT 
3 cDNA. A DNA fragment similar in size (1.5 kb) to 
the GLUT 3 cDNA was detected in different clones 
of D23/GLUT 3 transfectants, but not in D23, or 
D23/MMTV myoblasts (Fig. 4). More importantly, 
GLUT 3 expression was induced upon incubation of 
D23/GLUT 3 myoblasts (clones 2-4 and 2-6) with 
-1.5 kb 
l 2 3 4 5 6 7 8 9 l0 l l  12 13 14 
Fig. 4. Southern blot analysis of D23/GLUT 3 transfectants. 
Genomic DNAs from D23 transfectants were digested with 
EcoRV and HindIII. After electrophoresis and transfer to an 
ICN Biotrans membrane, the blot was probed with the GLUT 
3 cDNA. No band was detected in the controls: D23 myoblast 
(lane l) and D23/MMTV transfectant (lane 2). A 1.5 kb band 
was observed in D23/GLUT 3 transfectant clones 2-1, 2-2, 2-4, 
2-6, 2-7, 2-8, 2-9, 2-11 and 2-12 (lanes 3, 4, 6, 8, 9, 10, 11, 13 
and 14, respectively); this band was not detected in D23/GLUT 
3 clone 2-3, 2-5 and 2-10 transfectants (lanes 5, 7 and 12, re- 
spectively). 
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Fig. 5. Northern blot analysis of D23/GLUT 3 transfectants. 
Northern blot analysis was carried out as described in the text. 
D23 transfectants were treated with or without 1 × 10 _7 M dexa- 
methasone (dex). Two gg of poly(A)+RNA were loaded into 
each lane. After electrophoresis and transfer to Biotrans mem- 
brane, the blot was probed with GLUT 3, myogenin, and ~2-mi- 
croglobulin (BMG) cDNAs (A, B and C, respectively). The 4.1 
kb endogenous GLUT 3 transcript was evident in L6 myoblast, 
but not in other cell lines (A). A transcript corresponding to 
the size of the exogenous GLUT 3 cDNA (1.5 kb) was detected 
in dex-induced D23/GLUT 3 transfectants 2-4 and 2-6, but not 
in uninduced cells. The other bands observed in the dex-in- 
duced transfectants were probably transcripts from genes that 
had integrated the exogenous GLUT 3 cDNA (A). The endoge- 
nous myogenin transcript level (1.9 kb) was evident only in L6 
myoblast, but not in other cell lines (B). RNA loading was in- 
dicated by probing with the BMG cDNA (C). 
0.1 ~tM dex (Fig. 5); their GLUT 3 transcript levels 
were at least 3-5 times higher than that of L6 cells. 
The ability of D23 transfectants o take up 2-de- 
oxy-o-glucose (dGlc) was examined (Fig. 6). Similar 
to D23 myoblast, D23/MMTV and uninduced D23/ 
GLUT 3 transfectants were unable to take up dGlc 
(0.06 mM). However, dex-induced D23/GLUT 3 
transfectants were able to take up dGlc at a rate 
slightly higher than that for the wild type L6 myo- 
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Fig. 6. Uptake of 2-deoxy-D-glucose by D23 transfectants. 
Transport studies were carried out as described in the text. 
Where applicable, cells were induced with 10 7 M dexametha- 
sone (de×) for 24 h. The uptake of 0.06 mM 2-deoxy-D-glucose 
was monitored over a 1 rain period. E, ©, ~, A, <>, and • 
denote the uptake by day 2 cultures of L6, D23, D23/MMTV 
(1-1), dex-induced D23/MMTV (1-1), D23/GLUT 3 (2-4) and 
dex-induced D23/GLUT 3 (2-4) myoblasts, respectively. The er- 
ror bars denote standard deviations for a sample size of 3. 
blast. This clearly demonstrated the presence of func- 
tional GLUT 3 transporters in dex-induced D23l 
GLUT 3 transfectants. These transfectants were 
therefore used to study the role of GLUT 3 in myo- 
genic differentiation. 
3.4. Biochemical and morphological differentiation of 
dex-induced D231GLUT 3 transfectants 
Poly(A)+RNAs from day 2 and day 6 cultures of 
dex-induced and uninduced transfectants were 
probed with myogenin, MHC, or TnT cDNAs. In- 
duction of GLUT 3 was found to have no effect on 
myogenin, MHC and TnT expression (Fig. 5 and 
data not shown). Immunofluorescence studies also 
failed to demonstrate he presence of myogenin and 
MHC in dex-induced or uninduced ay 6 D23 and 
D231GLUT 3 transfectants (Figs. 7 and 8, data not 
shown). These studies howed that overexpression f 
GLUT 3 did not activate myogenin or MHC expres- 
sion. An examination of cell morphology also failed 
to reveal the presence of myotubes in dex-induced 
D23/GLUT 3, D23 and D23/MMTV myoblasts 
(Figs. 7 and 8). Previous studies showed that about 
4-6% fusion was observed in day 6 cultures of dex- 
induced D23/GLUT 3 myoblasts [31]. 
Since overexpression of GLUT 3 also suppressed 
myogenesis [31], it was difficult to determine whether 
the myogenic defect of the dex-induced D23/GLUT 3 
transfectants was due to the much elevated GLUT 3 
transporter level, or some GLUT 3-independent 
events. Whatever be the case, this study suggests 
that mutant D23 is defective in regulatory compo- 
nent(s) essential for the expression of myogenin and 
muscle-specific genes, and these defects could not be 
restored by overexpression f the GLUT 3 transport- 
er. 
3.5. Myogenin promoter activities in L6 and D23 
myoblasts 
Another approach to characterize the myogenic 
defect of mutant D23 was to determine why D23 
myoblast was impaired in myogenin expression. To 
this end, myogenin promoter activity was examined 
by transfecting D23 and L6 cells with constructs con- 
taining the full-length (pGSC) or the truncated 
(pGXC) myogenin promoter [36]. In both constructs, 
a chloramphenicol acetyltransferase (CAT) gene was 
placed under the control of a myogenin promoter; 
the activity of which could then be monitored by 
the CAT activity. Cells were also co-transfected 
with a construct containing a lacZ gene placed under 
the control of a constitutive CMV promoter (pRc/ 
CMV-I~gal), this enabled one to determine the effi- 
ciency of transfection by measuring ~-galactosidase 
activity. 
Transient ransfectants of L6 cells harboring the 
full-length myogenin promoter (pGSC) were found 
- - - )  
Fig. 7. Immunofluorescence staining for myogenin in day 6 dex-induced cultures. Immunofluorescence studies were carried out as de- 
scribed in the text. Day 6 cultures of L6 (A-C), D23 (D-F), D23/MMTV (G-I), D23/GLUT 3 clones 2-4 (J-L) and D23/GLUT 3 
clone 2-6 (M-O) were induced with 10 7 M dex on day 1 for 24 h. A, D, G, J, and M indicate cell morphology as viewed by the 
phase contrast microscope. B, E, H, K and N indicate cells stained with Hoechst DNA stain. C, F, I, L and O indicate staining of 
myogenin by an anti-myogenin antibody (F5D). Myogenin staining was observed only in the nuclei of L6 myotubes (C), and not in 
other cultures (F, I, L, and O). 
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Fig. 8. Immunofluorescence staining for myosin heavy chain in 
day 6 dex-induced cultures. Day 6 cultures of L6 (A-C), D23 
(D-F), D23/MMTV clone 1-1 (G-I), D23/GLUT 3 clones 2-4 
(J-L) and D23/GLUT 3 clone 2-6 (M-O) were induced with 
10 -7 M dex on day 1 for 24 h. A, D, G, J, and M indicate cell 
morphology as viewed by the phase contrast microscope. B, E, 
H, K and N indicate cells stained with Hoechst DNA stain. C, 
F, I, L and O indicate staining of MHC by the anti-MHC anti- 
body (MF-20). MHC staining was observed only in L6 myo- 
tubes (C), and not in other cultures (F, I, L, and O). 
to possess ignificant levels of the myogenin promoter 
activity; only 35% of this activity was observed in L6 
cells containing the truncated myogenin promoter 
(pGXC) (Fig. 9). This was similar to the observation 
made by Yee et al. [36]. More importantly, less than 
10% of the myogenin promoter activity was observed 
in D23 myoblasts harboring similar constructs. This 
indicated that mutant D23 was defective in compo- 
nent(s) required for the myogenin promoter activity. 
MYOGENIN PROMOTER 
ACTIVITY 
lOO 
~ 80 
"~ ao 
.,~ 40 
2~ 
3/GXC 
CELL LINES 
Fig. 9. Myogenin promoter activities in L6 and D23 transfec- 
tants. Chloramphenicol acetyltransferase (CAT) and 13-galactosi- 
dase (13gal) activities were measured in L6 and D23 transient 
transfectants harboring a full-length (GSC) or truncated (GXC) 
myogenin promoter construct along with a pRc/CMV-13gal vec- 
tor. L6 and D23 transfectants containing the expression vector 
pRc/CMV were used as negative controls in assessing 13-galacto- 
sidase activity. Cells transfected with the Bluescript KS + vector 
were used as negative controls for measuring CAT activity. To 
normalize transfection efficiencies, the myogenin promoter activ- 
ity was measured as a ratio of the CAT and the I~gal activities. 
The myogenin promoter activity of L6/GSC transfectant was 
taken as 100%. The error bars denote standard eviations for a 
sample size of 4. 
-1.5 kb 
1 2 3 4 5 6 7 8 9 
Fig. 10. Southern blot analysis of D23/myogenin transfectants. 
Genomic DNAs from D23/myogenin transfectants were digested 
with XhoI and BamHI. Southern blot studies were carried out 
as described in Fig. 4. Lanes: 1, myogenin cDNA digested with 
XhoI and BamHI; 2 and 3, genomic DNAs of D23 and D23/ 
PKJ1AR clone 1-6, respectively; 4-9, DNAs from D23/myoge- 
nin transfectants clones 2-5, 2-3, 1-6, 1-5, 1-4, and 1-2, respec- 
tively. 
3.6. Transfection of D23 myoblast with a myogenin 
cDNA 
If the deficiency in myogenin expression is solely 
responsible for the myogenic defect in D23 myoblast, 
then expression of an exogenous myogenin cDNA 
may restore its myogenic ability. To examine this 
possibility, mutant D23 was transfected with a con- 
struct (PGK-myogenin) containing the myogenin 
coding sequence placed under the control of a con- 
stitutive phosphoglycerate kinase promoter (PGK) or 
with its control vector (PKJ1AR). These cells were 
co-transfected with the pRc/CMV-13gal vector (which 
contained the neomycin gene) to allow selection of 
stable transfectants using G418. 
Genomic DNAs from D23 transfectants were pre- 
pared and digested with XhoI and BamHI. Signifi- 
cant levels of the exogenous myogenin cDNA (1.5 
kb) were detected in a number of D23/myogenin 
transfectants (clones 1-2, 1-6, 1-10, 2-3, 2-5 and 2- 
7), but not in D23 or D23/PKJ1AR myoblasts (Fig. 
10). More importantly, myogenin expression was de- 
tected in day 4.5 cultures of L6 cells and in D23/ 
myogenin transfectants, but not in D23 or D23/ 
PKJ1AR myoblasts (Fig. 11). Despite their much 
elevated myogenin transcript levels, these D23/myo- 
genin transfectants were still devoid of the MLC, 
MHC and TnT transcripts, which were present in 
very high levels in L6 cultures (Fig. 11 and data 
not shown). These studies therefore showed that 
overexpression of myogenin i D23/myogenin trans- 
fectants was not accompanied by increased expres- 
sion of muscle-specific genes. 
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Fig. 11. Northern blot analysis of D23/myogenin transfectants. 
Northern blot analysis was carried out as described in the text. 
Poly(A)+RNAs were extracted from day 4.5 cultures. Two p,g 
of sample were loaded onto each lane. The blots were probed 
with 32p-labeled MLC (A), myogenin (B) and ~2-rnicroglobulin 
(BMG) cDNAs (C). 
Immunofluorescence studies also revealed the pres- 
ence of myogenin in day 6 cultures of L6 and D23/ 
myogenin cells, but not in D23 or D23/PKJ1AR 
myoblasts (Fig. 12). More importantly, MHC could 
not be detected in D23/myogenin transfectants, even 
though this protein was readily detected in L6 myo- 
blasts (Fig. 13). An examination of cell morphology 
also failed to detect myotubes in day 6 cultures of 
D23/myogenin, D23 or D23/PKJ1AR myoblasts, 
whereas these structures were clearly visible in L6 
cultures (Figs. 12 and 13). The inability of D23/myo- 
genin transfectants to express MHC, MLC and TnT 
genes, and to form myotubes uggests that mutant 
D23 is also defective in component(s) essential for 
the transcription of muscle-specific genes. These 
component(s) are required even in the presence of 
excess amount of myogenin. They may act in con- 
4. Discussion 
Myogenic differentiation is controlled by very 
complex regulatory events. Studies using myogene- 
sis-defective myoblast mutants suggested that the 
temporal order of in vitro expression of myogenic 
components was Myf-5, myogenin and muscle-specif- 
ic contractile proteins [2]. Overexpression f GLUT 3 
in L6 myoblast (as in L6 GLUT 3 sense transfec- 
tants) suppressed not only expression of myogenin 
and muscle-specific genes (MLC, MHC, and TnT), 
but also myotube formation [31]. Reduction of 
GLUT 3 expression to about 39% of the L6 level 
(as in L6 GLUT 3 antisense transfectants) also in- 
hibited myogenin expression; however, this had no 
effect on the expression of muscle-specific genes 
and on the rates of fusion [31]. 
To further investigate the relationship between 
GLUT 3 and the myogenic pathway, the myogenic 
properties of three independently isolated GLUT 3- 
mutants (D2, D9 and D23) were first examined (Figs. 
1-3). Even though these mutants possessed similarly 
reduced GLUT 3 transcript levels, they differed con- 
siderably in the expression of myogenesis-associated 
genes and in the rate of myotube formation. These 
mutants were therefore likely altered in different 
myogenic regulatory components. Since mutant 
D23 is essentially devoid of transcripts for myogenin 
and muscle-specific genes and is unable to form myo- 
tubes, it can serve as a useful tool to study the 
GLUT 3-associated myogenic pathway. 
To explore the role of GLUT 3 in myogenic differ- 
entiation, mutant D23 was transfected with a GLUT 
3 cDNA placed under the control of a dexametha- 
sone-inducible MMTV promoter. Elevated levels of 
the GLUT 3 transcript and functional GLUT 3 
transporter were observed upon induction of the 
D23/GLUT 3 transfectants with dexamethasone 
Fig. 12. Immunofluorescence staining of myogenin in day 6 D23/myogenin transfectants. Day 6 cultures of L6 (A-C), D23 (D-F), 
D23/PKJ1AR (G-I), D23/myogenin clone 1-6 U-L), and D23/myogenin clone 2-5 (M-O) were examined in this study. A, D, G, J, 
and M indicate cell morphology as viewed by the phase contrast microscope. B, E, H, K and N indicate cells stained with Hoechst 
DNA stain. C, F, I, L and O indicate staining of myogenin by the anti-myogenin antibody (F5D). 
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(Figs. 5 and 6). It was important o note that these 
changes were not accompanied by increases in myo- 
genin or MHC levels (Figs. 5, 7 and 8). Since over- 
expression of GLUT 3 in L6 myoblasts also sup- 
pressed myogenesis [31], it was difficult to de- 
termine whether the myogenic defect of the dex- 
induced D231GLUT 3 transfectants was due to ele- 
vated GLUT 3 level, or some GLUT 3-independent 
events. 
To gain more insight into the inability of mutant 
D23 to express myogenin, its myogenin promoter ac- 
tivity was examined by transfection studies using 
constructs containing a chlorarnphenicol acetyltrans- 
ferase (CAT) gene placed under the control of a myo- 
genin promoter (Fig. 9). Unlike L6 transfectants, 
myogenin promoter activity was hardly detectable 
in D23 transfectants. This suggested that mutant 
D23 was deficient in component(s) (hereafter referred 
to as Factor M) required for the myogenin promoter 
activity. Since rnyogenin expression was also reduced 
in L6 transfectants over- or underexpressing the 
GLUT 3 transporter [31], this factor might also be 
altered in these L6 transfectants. If so, then the levels 
and/or functional states of Factor M were probably 
dependent on a critical level of the GLUT 3 trans- 
porter. 
If the inability of D23 myoblast to express muscle- 
specific transcripts was solely due to the absence of 
myogenin, then increased levels of myogenin should 
restore its myogenic ability. To explore this possibil- 
ity, mutant D23 was transfected with a construct 
containing the myogenin coding sequence. Despite 
overexpression of myogenin in these cells, these 
D23/myogenin transfectants were still unable to ex- 
press MLC, MHC and TnT genes and to form myo- 
tubes (Figs. 11-13, and data not shown). Thus mu- 
tant D23 might also be defective in a component 
(Factor S) required for activating MLC, MHC, and 
TnT transcription. This factor is required for myo- 
genesis even in the presence of an excess amount of 
myogenin. Since the myogenic defect of L6 GLUT 3 
sense transfectants was due to the inability to express 
muscle-specific genes, and not due to insufficient 
myogenin [31], Factor S might also be absent or 
defective in these L6 GLUT 3 sense transfectants. 
We have shown in this study that mutant D23 is 
deficient in components responsible for myogenin ex- 
pression and for the transcription of muscle-specific 
genes. Even though all GLUT 3- mutants possessed 
similar GLUT 3 levels, mutant D23 had more re- 
duced myogenin and muscle-specific transcripts than 
D2 and D9 myoblasts (Fig. 3). This together with the 
inability of GLUT 3 to restore myogenesis suggested 
that GLUT 3 was not solely responsible the myogen- 
ic defects in mutant D23 (Figs. 5, 7 and 8). This 
mutant is probably deficient in a regulatory factor 
(R), which controls the expression of GLUT 3, Fac- 
tor M and Factor S. On the other hand, D2 and D9 
myoblasts may be mutated in Factor R or in GLUT 
3 itself, such that only GLUT 3 expression is directly 
affected, whereas expression of Factor M and Factor 
S is still possible. The observed reduced expression of 
myogenin and muscle-specific genes could be due to 
reduced GLUT 3 level in these mutants [31]. This 
may explain why these mutants till possess myoge- 
nin, MLC, and TnT transcripts and the ability to 
form myotubes (Figs. 2 and 3). 
An important assumption of this model is that the 
observed changes are due to mutation of a single 
regulatory gene in mutant D23, namely the one cod- 
ing for Factor R. Since mutant D23 is a spontaneous 
mutant [19], the chances of this mutant acquiring 
simultaneous mutations in GLUT 3, Factor M, and 
Factor S are fairly remote. Since the frequency of 
spontaneous mutation is around 10 -6 , the frequency 
of three simultaneous mutations should then be 
around 10 -aS. In other words, it is virtually impos- 
sible to obtain mutants acquiring three simultaneous 
mutations. 
In summary, we have shown in this study that the 
rat myoblast GLUT 3- mutant, D23, is deficient in 
factors required for the myogenin promoter activity, 
and for the transcription of muscle-specific contrac- 
tile protein genes. These changes may be brought 
Fig. 13. Immunofluorescence staining of MHC in day 6 D23/myogenin transfectants. Day 6 cultures of L6 (A-C), D23 (D-F), D23/ 
PKJ1AR (G-I), D23/myogenin clone 1-6 (J-L) and D23/myogenin clone 2-5 (M-O) were examined in this study. A, D, G, J, and M 
indicate cell morphology as viewed by the phase contrast microscope. B, E, H, K and N indicate cells stained with Hoechst DNA 
stain. C, F, I, L and O indicate staining of an anti-MHC antibody (MF-20). 
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about by reduced level of a regulatory component, 
which also controls the expression of the GLUT 3 
transporter. 
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